ffective glycemic control can forestall the onset and advancement of diabetes-related microand macrovascular complications (1,2). However, the use of certain antihyperglycemic medications, namely insulin and insulin secretagogues, to treat type 1 or type 2 diabetes can result in hypoglycemia, a clinical syndrome characterized by abnormally low blood glucose (1,2). Optimal diabetes management is thus a delicate balance between treating hyperglycemia and avoiding the immediate risk of hypoglycemia (3).Hypoglycemia can result in serious physical (4,5) and psychosocial (6-9) morbidity, and mortality (5,10-14).Neurogenic symptoms include tremor, palpitations, anxiety, sweating, pallor, and hunger, whereas neuroglycopenic symptoms include cognitive impairment, behavioral changes, psychomotor abnormalities, seizures, and coma (15). Hypoglycemia can affect both quality of life and productivity for people with type 1 or type 2 diabetes (16)(17)(18)(19). Consequently, the risk and experience of hypoglycemia have been connected to a range of emotional responses, including fear, anxiety, and concerns about safety (7,20,21).Frequency and severity of hypoglycemia have been found to be associated with psychological distress and a level